Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Boosting Bacteroides vulgatus in diabetic mice increased GLP-1 secretion, improving blood sugar control and reducing sugar ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

The presentation scheduled for Tuesday, February 11th at 12:40-1:10 PM ET in Track 1 will feature a business overview and update by Miranda Toledano, the Company’s Chief Executive Officer.

A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...